# US 2021/0341492 A1 · Newborn screening for primary immunodeficiencies, cystinosis, and wilson disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0341492 A1
- Document ID: US20210341492A1
- Status: Published application
- Kind: A1
- Application number: 17/282,989
- Filed: 2019-10-04
- Published: 2021-11-04
- Earliest claimed: 2018-10-05
- Assignees: Seattle Children's Hospital d/b/a Seattle Children's Research Institute; Fred Hutchinson Cancer Research Center
- Applicants: Seattle Children's Hospital d/b/a Seattle Children's Research Institute; Fred Hutchinson Cancer Research Center
- Inventors: Sihoun Hahn; Sunhee Jung; Jeffrey Whiteaker; Troy Torgerson; Amanda Paulovich; Christopher Collins; Remwilyn Dayuha
- Web page: https://patentgrep.com/patent/US20210341492A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- C07K 16/18: against material from animals or humans
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- G01N 2800/24: Immunology or allergic disorders
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Newborn screening for primary immunodeficiencies, cystinosis, and Wilson disease is described. The newborn screening can detect these disorders from dried blood spots already routinely collected at the time of birth. Early detection of these disorders will greatly improve patient outcome as each of them can be fatal once symptoms emerge.

## Claims

### Claim 1

A method of screening for severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), and/or X-linked agammaglobulinemia (XLA) in a subject, the method comprising:
Obtaining a dried blood spot (DBS) sample derived from the subject;
Digesting proteins from blood of the DBS with an enzyme to yield one or more peptides;
Enriching for:
a CD3ε signature peptide of SCID of SEQ ID NO: 1 with an antibody or antigen-binding fragment thereof that binds the CD3ε signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 22, CDR2 of SEQ ID NO: 23, and CDR3 of SEQ ID NO: 24, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 25, CDR2 of SEQ ID NO: 26, and CDR3 of SEQ ID NO: 27;
a first WASp signature peptide of WAS of SEQ ID NO: 2 with an antibody or antigen-binding fragment thereof that binds the first WASp signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 28, CDR2 of SEQ ID NO: 29, and CDR3 of SEQ ID NO: 30, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 31, CDR2 of SEQ ID NO: 32, and CDR3 of SEQ ID NO: 33;
a second WASp signature peptide of WAS of SEQ ID NO: 3 with an antibody or antigen-binding fragment thereof that binds the second WASp signature peptide;
a first BTK signature peptide of XLA of SEQ ID NO: 4 with an antibody or antigen-binding fragment thereof that binds the first BTK signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 34, CDR2 of SEQ ID NO: 35, and CDR3 of sequence GDI, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 36, CDR2 of SEQ ID NO: 37, and CDR3 of SEQ ID NO: 38; and/or
a second BTK signature peptide of XLA of SEQ ID NO: 5 with an antibody or antigen-binding fragment thereof that binds the second BTK signature peptide;
Performing liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS) on the enriched peptides to determine concentrations of the peptides; and
Diagnosing the subject with:
SCID when the concentration of the CD3ε signature peptide is lower than a predetermined threshold concentration or when the CD3ε signature peptide is absent;
WAS when the concentrations of the first and/or second WASp signature peptides are lower than corresponding predetermined threshold concentrations or when the first and/or second WASp signature peptides are absent; and
XLA when the concentrations of the first and/or second BTK signature peptides are lower than corresponding predetermined threshold concentrations or when the first and/or second BTK signature peptides are absent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method is performed as part of a newborn screening (NBS) that additionally screens the subject for one or more of phenylketonuria, primary congenital hypothyroidism, cystic fibrosis, and sickle cell disease.

### Claim 3 (depends on 1)

The method of claim 1, wherein the method is performed in the absence of clinical symptoms of SCID, WAS, and/or XLA in the subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the enzyme is trypsin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the corresponding predetermined threshold concentration for each signature peptide is calculated from a standard deviation of the mean concentration of each signature peptide in DBS from a population of normal control subjects.

### Claim 6 (depends on 5)

The method of claim 5, wherein the mean concentration of the CD3ε signature peptide of SCID of SEQ ID NO: 1 in DBS from a population of normal control subjects comprises a concentration in a range of 70 pmol/L to 400 pmol/L.

### Claim 7 (depends on 5)

The method of claim 5, wherein the mean concentration of the first WASp signature peptide of WAS of SEQ ID NO: 2 in DBS from a population of normal control subjects comprises a concentration in a range of 600 pmol/L to 5000 pmol/L.

### Claim 8 (depends on 5)

The method of claim 5, wherein the mean concentration of the second WASp signature peptide of WAS of SEQ ID NO: 3 in DBS from a population of normal control subjects comprises a concentration in a range of 5500 pmol/L to 15000 pmol/L.

### Claim 9 (depends on 5)

The method of claim 5, wherein the mean concentration of the first BTK signature peptide of XLA of SEQ ID NO: 4 in DBS from a population of normal control subjects comprises a concentration in a range of 350 pmol/L to 2500 pmol/L.

### Claim 10 (depends on 5)

The method of claim 5, wherein the mean concentration of the second BTK signature peptide of XLA of SEQ ID NO: 5 in DBS from a population of normal control subjects comprises a concentration in a range of 550 pmol/L to 1600 pmol/L.

### Claim 11 (depends on 1)

The method of claim 1, wherein the antibody or antigen-binding fragment thereof used for enrichment of the CD3ε signature peptide of SCID of SEQ ID NO: 1 comprises a VH domain of SEQ ID NO: 63.

### Claim 12 (depends on 1)

The method of claim 1, wherein the antibody or antigen-binding fragment thereof used for enrichment of the CD3ε signature peptide of SCID of SEQ ID NO: 1 comprises a VL domain of SEQ ID NO: 64.

### Claim 13 (depends on 1)

The method of claim 1, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first WASp signature peptide of WAS of SEQ ID NO: 2 comprises a VH domain of SEQ ID NO: 65.

### Claim 14 (depends on 1)

The method of claim 1, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first WASp signature peptide of WAS of SEQ ID NO: 2 comprises a VL domain of SEQ ID NO: 66.

### Claim 15 (depends on 1)

The method of claim 1, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first WASp signature peptide of WAS of SEQ ID NO: 2 comprises a heavy chain of SEQ ID NO: 86.

### Claim 16 (depends on 1)

The method of claim 1, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first WASp signature peptide of WAS of SEQ ID NO: 2 comprises a light chain of SEQ ID NO: 91.

### Claim 17 (depends on 1)

The method of claim 1, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first BTK signature peptide of XLA of SEQ ID NO: 4 comprises a VH domain of SEQ ID NO: 67.

### Claim 18 (depends on 1)

The method of claim 1, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first BTK signature peptide of XLA of SEQ ID NO: 4 comprises a VL domain of SEQ ID NO: 68.

### Claim 19 (depends on 1)

The method of claim 1, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first BTK signature peptide of XLA of SEQ ID NO: 4 comprises a heavy chain of SEQ ID NO: 96.

### Claim 20 (depends on 1)

The method of claim 1, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first BTK signature peptide of XLA of SEQ ID NO: 4 comprises a light chain of SEQ ID NO: 101.

### Claim 21 (depends on 1)

The method of claim 1, wherein the method further comprises screening for cystinosis by enriching for:
a first CTNS signature peptide of cystinosis of SEQ ID NO: 6 with an antibody or antigen-binding fragment thereof that binds the first CTNS signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 39, CDR2 of SEQ ID NO: 40, and CDR3 of SEQ ID NO: 41, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 42, CDR2 of SEQ ID NO: 43, and CDR3 of SEQ ID NO: 44;
a second CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 with an antibody or antigen-binding fragment thereof that binds the second CTNS signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 45, CDR2 of SEQ ID NO: 46, and CDR3 of SEQ ID NO: 47, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 48, CDR2 of SEQ ID NO: 49, and CDR3 of SEQ ID NO: 50;
a third CTNS signature peptide of cystinosis of SEQ ID NO: 12 with an antibody or antigen-binding fragment thereof that binds the third CTNS signature peptide;
a fourth CTNS signature peptide of cystinosis of SEQ ID NO: 13 with an antibody or antigen-binding fragment thereof that binds the fourth CTNS signature peptide;
a first SHPK signature peptide of cystinosis of SEQ ID NO: 9 with an antibody or antigen-binding fragment thereof that binds the first SHPK signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 51, CDR2 of SEQ ID NO: 52, and CDR3 of SEQ ID NO: 53, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 54, CDR2 of SEQ ID NO: 55, and CDR3 of SEQ ID NO: 56;
a second SHPK signature peptide of cystinosis of SEQ ID NO: 14 with an antibody or antigen-binding fragment thereof that binds the second SHPK signature peptide;
a third SHPK signature peptide of cystinosis of SEQ ID NO: 15 with an antibody or antigen-binding fragment thereof that binds the third SHPK signature peptide;
and
Diagnosing the subject with cystinosis when the concentrations of the first CTNS, the second CTNS, the third CTNS, the fourth CTNS, the first SHPK, the second SHPK, and/or the third SHPK signature peptides are lower than corresponding predetermined threshold concentrations or when the first CTNS, the second CTNS, the third CTNS, the fourth CTNS, the first SHPK, the second SHPK, and/or the third SHPK signature peptides are absent.

### Claim 22 (depends on 21)

The method of claim 21, wherein the corresponding predetermined threshold concentration for each signature peptide is calculated from a standard deviation of the mean concentration of each signature peptide in DBS from a population of normal control subjects.

### Claim 23 (depends on 22)

The method of claim 22, wherein the mean concentration of the first CTNS signature peptide of cystinosis of SEQ ID NO: 6 in DBS from a population of normal control subjects comprises a concentration in a range of 40 pmol/L to 250 pmol/L.

### Claim 24 (depends on 22)

The method of claim 22, wherein the mean concentration of the first SHPK signature peptide of cystinosis of SEQ ID NO: 9 in DBS from a population of normal control subjects comprises a concentration in a range of 100 pmol/L to 8000 pmol/L.

### Claim 25 (depends on 21)

The method of claim 21, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first CTNS signature peptide of cystinosis of SEQ ID NO: 6 comprises a VH domain of SEQ ID NO: 69.

### Claim 26 (depends on 21)

The method of claim 21, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first CTNS signature peptide of cystinosis of SEQ ID NO: 6 comprises a VL domain of SEQ ID NO: 70.

### Claim 27 (depends on 21)

The method of claim 21, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first CTNS signature peptide of cystinosis of SEQ ID NO: 6 comprises a heavy chain of SEQ ID NO: 106.

### Claim 28 (depends on 21)

The method of claim 21, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first CTNS signature peptide of cystinosis of SEQ ID NO: 6 comprises a light chain of SEQ ID NO: 111.

### Claim 29 (depends on 21)

The method of claim 21, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 comprises a VH domain of SEQ ID NO: 71.

### Claim 30 (depends on 21)

The method of claim 21, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 comprises a VL domain of SEQ ID NO: 72.

### Claim 31 (depends on 21)

The method of claim 21, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 comprises a heavy chain of SEQ ID NO: 116.

### Claim 32 (depends on 21)

The method of claim 21, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 comprises a light chain of SEQ ID NO: 121.

### Claim 33 (depends on 21)

The method of claim 21, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first SHPK signature peptide of cystinosis of SEQ ID NO: 9 comprises a VH domain of SEQ ID NO: 73.

### Claim 34 (depends on 21)

The method of claim 21, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first SHPK signature peptide of cystinosis of SEQ ID NO: 9 comprises a VL domain of SEQ ID NO: 74.

### Claim 35 (depends on 21)

The method of claim 21, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first SHPK signature peptide of cystinosis of SEQ ID NO: 9 comprises a heavy chain of SEQ ID NO: 126.

### Claim 36 (depends on 21)

The method of claim 21, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first SHPK signature peptide of cystinosis of SEQ ID NO: 9 comprises a light chain of SEQ ID NO: 131.

### Claim 37 (depends on 1)

The method of claim 1, wherein the method further comprises screening for Wilson Disease (WD) by enriching for:
a first ATP7B signature peptide of WD of SEQ ID NO: 10 with an antibody or antigen-binding fragment thereof that binds the first ATP7B signature peptide; and/or
a second ATP7B signature peptide of WD of SEQ ID NO: 11 or 21 with an antibody or antigen-binding fragment thereof that binds the second ATP7B signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 57, CDR2 of SEQ ID NO: 58, and CDR3 of SEQ ID NO: 59, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 60, CDR2 of SEQ ID NO: 61, and CDR3 of SEQ ID NO: 62;
a third ATP7B signature peptide of WD of SEQ ID NO: 16 with an antibody or antigen-binding fragment thereof that binds the third ATP7B signature peptide;
a fourth ATP7B signature peptide of WD of SEQ ID NO: 17 with an antibody or antigen-binding fragment thereof that binds the fourth ATP7B signature peptide;
a fifth ATP7B signature peptide of WD of SEQ ID NO: 18 with an antibody or antigen-binding fragment thereof that binds the fifth ATP7B signature peptide;
a sixth ATP7B signature peptide of WD of SEQ ID NO: 19 with an antibody or antigen-binding fragment thereof that binds the sixth ATP7B signature peptide;
a seventh ATP7B signature peptide of WD of SEQ ID NO: 20 with an antibody or antigen-binding fragment thereof that binds the seventh ATP7B signature peptide; and
Diagnosing the subject with WD when the concentrations of the first ATP7B, the second ATP7B, the third ATP7B, the fourth ATP7B, the fifth ATP7B, the sixth ATP7B, and/or the seventh ATP7B signature peptides are lower than corresponding predetermined threshold concentrations or when the first ATP7B, the second ATP7B, the third ATP7B, the fourth ATP7B, the fifth ATP7B, the sixth ATP7B, and/or the seventh ATP7B signature peptides are absent.

### Claim 38 (depends on 37)

The method of claim 37, wherein the corresponding predetermined threshold concentration for each signature peptide is calculated from a standard deviation of the mean concentration of each signature peptide in DBS from a population of normal control subjects.

### Claim 39 (depends on 38)

The method of claim 38, wherein the mean concentration of the second ATP7B signature peptide of WD of SEQ ID NO: 11 or 21 in DBS from a population of normal control subjects comprises a concentration in a range of 90 pmol/L to 400 pmol/L.

### Claim 40 (depends on 38)

The method of claim 38, wherein the mean concentration of the third ATP7B signature peptide of WD of SEQ ID NO: 16 in DBS from a population of normal control subjects comprises a concentration in a range of 30 pmol/L to 100 pmol/L.

### Claim 41 (depends on 38)

The method of claim 38, wherein the mean concentration of the seventh ATP7B signature peptide of WD of SEQ ID NO: 20 in DBS from a population of normal control subjects comprises a concentration in a range of 200 pmol/L to 500 pmol/L.

### Claim 42 (depends on 37)

The method of claim 37, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second ATP7B signature peptide of WD of SEQ ID NO: 11 or 21 comprises a VH domain of SEQ ID NO: 75.

### Claim 43 (depends on 37)

The method of claim 37, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second ATP7B signature peptide of WD of SEQ ID NO: 11 or 21 comprises a VL domain of SEQ ID NO: 76.

### Claim 44 (depends on 37)

The method of claim 37, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second ATP7B signature peptide of WD of SEQ ID NO: 11 or 21 comprises a heavy chain of SEQ ID NO: 136.

### Claim 45 (depends on 37)

The method of claim 37, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second ATP7B signature peptide of WD of SEQ ID NO: 11 or 21 comprises a light chain of SEQ ID NO: 141.

### Claim 46

A method of screening for severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), and/or X-linked agammaglobulinemia (XLA) in a subject, the method comprising:
Obtaining a dried blood spot (DBS) sample derived from the subject;
Digesting proteins from blood of the DBS with an enzyme to yield one or more peptides;
Enriching for:
a CD3ε signature peptide of SCID of SEQ ID NO: 1 with an antibody or antigen-binding fragment thereof that binds the CD3ε signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 22, CDR2 of SEQ ID NO: 23, and CDR3 of SEQ ID NO: 24, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 25, CDR2 of SEQ ID NO: 26, and CDR3 of SEQ ID NO: 27;
a first WASp signature peptide of WAS of SEQ ID NO: 2 with an antibody or antigen-binding fragment thereof that binds the first WASp signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 28, CDR2 of SEQ ID NO: 29, and CDR3 of SEQ ID NO: 30, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 31, CDR2 of SEQ ID NO: 32, and CDR3 of SEQ ID NO: 33;
a second WASp signature peptide of WAS of SEQ ID NO: 3 with an antibody or antigen-binding fragment thereof that binds the second WASp signature peptide;
a first BTK signature peptide of XLA of SEQ ID NO: 4 with an antibody or antigen-binding fragment thereof that binds the first BTK signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 34, CDR2 of SEQ ID NO: 35, and CDR3 of sequence GDI, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 36, CDR2 of SEQ ID NO: 37, and CDR3 of SEQ ID NO: 38; and/or
a second BTK signature peptide of XLA of SEQ ID NO: 5 with an antibody or antigen-binding fragment thereof that binds the second BTK signature peptide;
Enriching for an endogenous ATP7B peptide of:
SEQ ID NO: 10 with an antibody or antigen binding fragment thereof that binds the endogenous ATP7B peptide of SEQ ID NO: 10;
SEQ ID NO: 11 or 21 with an antibody or antigen-binding fragment thereof that binds the endogenous ATP7B peptide of SEQ ID NO: 11 or 21 and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 57, CDR2 of SEQ ID NO: 58, and CDR3 of SEQ ID NO: 59, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 60, CDR2 of SEQ ID NO: 61, and CDR3 of SEQ ID NO: 62;
SEQ ID NO: 16 with an antibody or antigen-binding fragment thereof that binds the endogenous ATP7B peptide of SEQ ID NO: 16;
SEQ ID NO: 17 with an antibody or antigen-binding fragment thereof that binds the endogenous ATP7B peptide of SEQ ID NO: 17;
SEQ ID NO: 18 with an antibody or antigen-binding fragment thereof that binds the endogenous ATP7B peptide of SEQ ID NO: 18;
SEQ ID NO: 19 with an antibody or antigen-binding fragment thereof that binds the endogenous ATP7B peptide of SEQ ID NO: 19;
SEQ ID NO: 20 with an antibody or antigen-binding fragment thereof that binds the endogenous ATP7B peptide of SEQ ID NO: 20; or
SEQ ID NO: 21 with an antibody or antigen-binding fragment thereof that binds the endogenous ATP7B peptide of SEQ ID NO: 21;
Performing liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS) on the enriched peptides to determine concentrations of the peptides;
Calculating a ratio of signature peptide concentration:endogenous ATP7B peptide concentration for each signature peptide; and
Diagnosing the subject with:
SCID when the ratio of CD3ε signature peptide concentration:endogenous ATP7B peptide concentration is lower than a corresponding predetermined threshold ratio or when the CD3ε signature peptide is absent;
WAS when the ratios of the first and/or second WASp signature peptide concentration:endogenous ATP7B peptide concentration are lower than corresponding predetermined threshold ratios or when the first and/or second WASp signature peptides are absent; and
XLA when the ratios of the first and/or second BTK signature peptide concentration:endogenous ATP7B peptide concentration are lower than corresponding predetermined threshold ratios or when the first and/or second BTK signature peptides are absent.

### Claim 47 (depends on 46)

The method of claim 46, wherein each predetermined threshold ratio is calculated from standard deviation of the mean ratio of each peptide concentration:endogenous ATP7B peptide concentration in a population of samples.

### Claim 48 (depends on 46)

The method of claim 46, wherein the method is performed as part of a newborn screening (NBS) that additionally screens the subject for one or more of phenylketonuria, primary congenital hypothyroidism, cystic fibrosis, and sickle cell disease.

### Claim 49 (depends on 46)

The method of claim 46, wherein the method is performed in the absence of clinical symptoms of SCID, WAS, and/or XLA in the subject.

### Claim 50 (depends on 46)

The method of claim 46, wherein the enzyme is trypsin.

### Claim 51 (depends on 46)

The method of claim 46, wherein the antibody or antigen-binding fragment thereof used for enrichment of the CD3ε signature peptide of SCID of SEQ ID NO: 1 comprises a VH domain of SEQ ID NO: 63.

### Claim 52 (depends on 46)

The method of claim 46, wherein the antibody or antigen-binding fragment thereof used for enrichment of the CD3ε signature peptide of SCID of SEQ ID NO: 1 comprises a VL domain of SEQ ID NO: 64.

### Claim 53 (depends on 46)

The method of claim 46, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first WASp signature peptide of WAS of SEQ ID NO: 2 comprises a VH domain of SEQ ID NO: 65.

### Claim 54 (depends on 46)

The method of claim 46, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first WASp signature peptide of WAS of SEQ ID NO: 2 comprises a VL domain of SEQ ID NO: 66.

### Claim 55 (depends on 46)

The method of claim 46, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first WASp signature peptide of WAS of SEQ ID NO: 2 comprises a heavy chain of SEQ ID NO: 86.

### Claim 56 (depends on 46)

The method of claim 46, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first WASp signature peptide of WAS of SEQ ID NO: 2 comprises a light chain of SEQ ID NO: 91.

### Claim 57 (depends on 46)

The method of claim 46, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first BTK signature peptide of XLA of SEQ ID NO: 4 comprises a VH domain of SEQ ID NO: 67.

### Claim 58 (depends on 46)

The method of claim 46, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first BTK signature peptide of XLA of SEQ ID NO: 4 comprises a VL domain of SEQ ID NO: 68.

### Claim 59 (depends on 46)

The method of claim 46, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first BTK signature peptide of XLA of SEQ ID NO: 4 comprises a heavy chain of SEQ ID NO: 96.

### Claim 60 (depends on 46)

The method of claim 46, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first BTK signature peptide of XLA of SEQ ID NO: 4 comprises a light chain of SEQ ID NO: 101.

### Claim 61 (depends on 46)

The method of claim 46, further comprising screening for cystinosis by enriching for:
a first CTNS signature peptide of cystinosis of SEQ ID NO: 6 with an antibody or antigen-binding fragment thereof that binds the first CTNS signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 39, CDR2 of SEQ ID NO: 40, and CDR3 of SEQ ID NO: 41, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 42, CDR2 of SEQ ID NO: 43, and CDR3 of SEQ ID NO: 44;
a second CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 with an antibody or antigen-binding fragment thereof that binds the second CTNS signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 45, CDR2 of SEQ ID NO: 46, and CDR3 of SEQ ID NO: 47, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 48, CDR2 of SEQ ID NO: 49, and CDR3 of SEQ ID NO: 50;
a third CTNS signature peptide of cystinosis of SEQ ID NO: 12 with an antibody or antigen-binding fragment thereof that binds the third CTNS signature peptide;
a fourth CTNS signature peptide of cystinosis of SEQ ID NO: 13 with an antibody or antigen-binding fragment thereof that binds the fourth CTNS signature peptide;
a first SHPK signature peptide of cystinosis of SEQ ID NO: 9 with an antibody or antigen-binding fragment thereof that binds the first SHPK signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 51, CDR2 of SEQ ID NO: 52, and CDR3 of SEQ ID NO: 53, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 54, CDR2 of SEQ ID NO: 55, and CDR3 of SEQ ID NO: 56;
a second SHPK signature peptide of cystinosis of SEQ ID NO: 14 with an antibody or antigen-binding fragment thereof that binds the second SHPK signature peptide; and/or
a third SHPK signature peptide of cystinosis of SEQ ID NO: 15 with an antibody or antigen-binding fragment thereof that binds the third SHPK signature peptide;
Calculating a ratio of signature peptide concentration:endogenous ATP7B peptide concentration for each signature peptide; and
Diagnosing the subject with cystinosis when the ratio of the first CTNS peptide concentration:endogenous ATP7B peptide concentration, the second CTNS peptide concentration:endogenous ATP7B peptide concentration, the third CTNS peptide concentration:endogenous ATP7B peptide concentration, the fourth CTNS peptide concentration:endogenous ATP7B peptide concentration, the first SHPK peptide concentration:endogenous ATP7B peptide concentration, the second SHPK peptide concentration:endogenous ATP7B peptide concentration, and/or the third SHPK signature peptide concentration:endogenous ATP7B peptide concentration is lower than a corresponding predetermined threshold ratio or when the first CTNS, the second CTNS, the third CTNS, the fourth CTNS, the first SHPK, the second SHPK, and/or the third SHPK signature peptides are absent.

### Claim 62 (depends on 61)

The method of claim 61, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first CTNS signature peptide of cystinosis of SEQ ID NO: 6 comprises a VH domain of SEQ ID NO: 69.

### Claim 63 (depends on 61)

The method of claim 61, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first CTNS signature peptide of cystinosis of SEQ ID NO: 6 comprises a VL domain of SEQ ID NO: 70.

### Claim 64 (depends on 61)

The method of claim 61, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first CTNS signature peptide of cystinosis of SEQ ID NO: 6 comprises a heavy chain of SEQ ID NO: 106.

### Claim 65 (depends on 61)

The method of claim 61, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first CTNS signature peptide of cystinosis of SEQ ID NO: 6 comprises a light chain of SEQ ID NO: 111.

### Claim 66 (depends on 61)

The method of claim 61, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 comprises a VH domain of SEQ ID NO: 71.

### Claim 67 (depends on 61)

The method of claim 61, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 comprises a VL domain of SEQ ID NO: 72.

### Claim 68 (depends on 61)

The method of claim 61, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 comprises a heavy chain of SEQ ID NO: 116.

### Claim 69 (depends on 61)

The method of claim 61, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 comprises a light chain of SEQ ID NO: 121.

### Claim 70 (depends on 61)

The method of claim 61, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first SHPK signature peptide of cystinosis of SEQ ID NO: 9 comprises a VH domain of SEQ ID NO: 73.

### Claim 71 (depends on 61)

The method of claim 61, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first SHPK signature peptide of cystinosis of SEQ ID NO: 9 comprises a VL domain of SEQ ID NO: 74.

### Claim 72 (depends on 61)

The method of claim 61, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first SHPK signature peptide of cystinosis of SEQ ID NO: 9 comprises a heavy chain of SEQ ID NO: 126.

### Claim 73 (depends on 61)

The method of claim 61, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first SHPK signature peptide of cystinosis of SEQ ID NO: 9 comprises a light chain of SEQ ID NO: 131.

### Claim 74 (depends on 61)

The method of claim 61, wherein the antibody or antigen-binding fragment thereof used for enrichment of the endogenous ATP7B peptide of SEQ ID NO: 11 or 21 comprises a VH domain of SEQ ID NO: 75.

### Claim 75 (depends on 61)

The method of claim 61, wherein the antibody or antigen-binding fragment thereof used for enrichment of the endogenous ATP7B signature peptide of SEQ ID NO: 11 or 21 comprises a VL domain of SEQ ID NO: 76.

### Claim 76 (depends on 61)

The method of claim 61, wherein the antibody or antigen-binding fragment thereof used for enrichment of the endogenous ATP7B signature peptide of SEQ ID NO: 11 or 21 comprises a heavy chain of SEQ ID NO: 136.

### Claim 77 (depends on 61)

The method of claim 61, wherein the antibody or antigen-binding fragment thereof used for enrichment of the endogenous ATP7B signature peptide of SEQ ID NO: 11 or 21 comprises a light chain of SEQ ID NO: 141.

### Claim 78

A method of detecting one or more signature peptides of severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), and/or X-linked agammaglobulinemia (XLA) in one or more dried blood spot (DBS) samples, the method comprising:
Obtaining the one or more dried blood spot (DBS) samples;
Digesting proteins from blood of each DBS with an enzyme to yield one or more peptides;
Enriching for:
a CD3ε signature peptide of SCID of SEQ ID NO: 1 with an antibody or antigen-binding fragment thereof that binds the CD3ε signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 22, CDR2 of SEQ ID NO: 23, and CDR3 of SEQ ID NO: 24, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 25, CDR2 of SEQ ID NO: 26, and CDR3 of SEQ ID NO: 27;
a first WASp signature peptide of WAS of SEQ ID NO: 2 with an antibody or antigen-binding fragment thereof that binds the first WASp signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 28, CDR2 of SEQ ID NO: 29, and CDR3 of SEQ ID NO: 30, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 31, CDR2 of SEQ ID NO: 32, and CDR3 of SEQ ID NO: 33;
a second WASp signature peptide of WAS of SEQ ID NO: 3 with an antibody or antigen-binding fragment thereof that binds the second WASp signature peptide;
a first BTK signature peptide of XLA of SEQ ID NO: 4 with an antibody or antigen-binding fragment thereof that binds the first BTK signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 34, CDR2 of SEQ ID NO: 35, and CDR3 of sequence GDI, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 36, CDR2 of SEQ ID NO: 37, and CDR3 of SEQ ID NO: 38; and/or
a second BTK signature peptide of XLA of SEQ ID NO: 5 with an antibody or antigen-binding fragment thereof that binds the second BTK signature peptide;
Performing liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS) on the enriched peptides, thus detecting one or more signature peptides of SCID, WAS, and XLA in one or more DBS samples.

### Claim 79 (depends on 78)

The method of claim 78, wherein the enzyme is trypsin.

### Claim 80 (depends on 78)

The method of claim 78, wherein the antibody or antigen-binding fragment thereof used for enrichment of the CD3ε signature peptide of SCID of SEQ ID NO: 1 comprises a VH domain of SEQ ID NO: 63.

### Claim 81 (depends on 78)

The method of claim 78, wherein the antibody or antigen-binding fragment thereof used for enrichment of the CD3ε signature peptide of SCID of SEQ ID NO: 1 comprises a VL domain of SEQ ID NO: 64.

### Claim 82 (depends on 78)

The method of claim 78, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first WASp signature peptide of WAS of SEQ ID NO: 2 comprises a VH domain of SEQ ID NO: 65.

### Claim 83 (depends on 78)

The method of claim 78, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first WASp signature peptide of WAS of SEQ ID NO: 2 comprises a VL domain of SEQ ID NO: 66.

### Claim 84 (depends on 78)

The method of claim 78, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first WASp signature peptide of WAS of SEQ ID NO: 2 comprises a heavy chain of SEQ ID NO: 86.

### Claim 85 (depends on 78)

The method of claim 78, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first WASp signature peptide of WAS of SEQ ID NO: 2 comprises a light chain of SEQ ID NO: 91.

### Claim 86 (depends on 78)

The method of claim 78, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first BTK signature peptide of XLA of SEQ ID NO: 4 comprises a VH domain of SEQ ID NO: 67.

### Claim 87 (depends on 78)

The method of claim 78, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first BTK signature peptide of XLA of SEQ ID NO: 4 comprises a VL domain of SEQ ID NO: 68.

### Claim 88 (depends on 78)

The method of claim 78, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first BTK signature peptide of XLA of SEQ ID NO: 4 comprises a heavy chain of SEQ ID NO: 96.

### Claim 89 (depends on 78)

The method of claim 78, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first BTK signature peptide of XLA of SEQ ID NO: 4 comprises a light chain of SEQ ID NO: 101.

### Claim 90 (depends on 78)

The method of claim 78, further comprising detecting one or more signature peptides of cystinosis by enriching for:
a first CTNS signature peptide of cystinosis of SEQ ID NO: 6 with an antibody or antigen-binding fragment thereof that binds the first CTNS signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 39, CDR2 of SEQ ID NO: 40, and CDR3 of SEQ ID NO: 41, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 42, CDR2 of SEQ ID NO: 43, and CDR3 of SEQ ID NO: 44;
a second CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 with an antibody or antigen-binding fragment thereof that binds the second CTNS signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 45, CDR2 of SEQ ID NO: 46, and CDR3 of SEQ ID NO: 47, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 48, CDR2 of SEQ ID NO: 49, and CDR3 of SEQ ID NO: 50;
a third CTNS signature peptide of cystinosis of SEQ ID NO: 12 with an antibody or antigen-binding fragment thereof that binds the third CTNS signature peptide;
a fourth CTNS signature peptide of cystinosis of SEQ ID NO: 13 with an antibody or antigen-binding fragment thereof that binds the fourth CTNS signature peptide;
a first SHPK signature peptide of cystinosis of SEQ ID NO: 9 with an antibody or antigen-binding fragment thereof that binds the first SHPK signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 51, CDR2 of SEQ ID NO: 52, and CDR3 of SEQ ID NO: 53, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 54, CDR2 of SEQ ID NO: 55, and CDR3 of SEQ ID NO: 56;
a second SHPK signature peptide of cystinosis of SEQ ID NO: 14 with an antibody or antigen-binding fragment thereof that binds the second SHPK signature peptide; and/or
a third SHPK signature peptide of cystinosis of SEQ ID NO: 15 with an antibody or antigen-binding fragment thereof that binds the third SHPK signature peptide;
Performing liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS) on the enriched peptides, thus detecting one or more signature peptides of cystinosis in one or more DBS samples.

### Claim 91 (depends on 90)

The method of claim 90, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first CTNS signature peptide of cystinosis of SEQ ID NO: 6 comprises a VH domain of SEQ ID NO: 69.

### Claim 92 (depends on 90)

The method of claim 90, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first CTNS signature peptide of cystinosis of SEQ ID NO: 6 comprises a VL domain of SEQ ID NO: 70.

### Claim 93 (depends on 90)

The method of claim 90, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first CTNS signature peptide of cystinosis of SEQ ID NO: 6 comprises a heavy chain of SEQ ID NO: 106.

### Claim 94 (depends on 90)

The method of claim 90, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first CTNS signature peptide of cystinosis of SEQ ID NO: 6 comprises a light chain of SEQ ID NO: 111.

### Claim 95 (depends on 90)

The method of claim 90, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 comprises a VH domain of SEQ ID NO: 71.

### Claim 96 (depends on 90)

The method of claim 90, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 comprises a VL domain of SEQ ID NO: 72.

### Claim 97 (depends on 90)

The method of claim 90, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 comprises a heavy chain of SEQ ID NO: 116.

### Claim 98 (depends on 90)

The method of claim 90, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 comprises a light chain of SEQ ID NO: 121.

### Claim 99 (depends on 90)

The method of claim 90, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first SHPK signature peptide of cystinosis of SEQ ID NO: 9 comprises a VH domain of SEQ ID NO: 73.

### Claim 100 (depends on 90)

The method of claim 90, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first SHPK signature peptide of cystinosis of SEQ ID NO: 9 comprises a VL domain of SEQ ID NO: 74.

### Claim 101 (depends on 90)

The method of claim 90, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first SHPK signature peptide of cystinosis of SEQ ID NO: 9 comprises a heavy chain of SEQ ID NO: 126.

### Claim 102 (depends on 90)

The method of claim 90, wherein the antibody or antigen-binding fragment thereof used for enrichment of the first SHPK signature peptide of cystinosis of SEQ ID NO: 9 comprises a light chain of SEQ ID NO: 131.

### Claim 103 (depends on 78)

The method of claim 78, further comprising detecting one or more signature peptides of Wilson Disease (WD) by enriching for:
a first ATP7B signature peptide of WD of SEQ ID NO: 10 with an antibody or antigen-binding fragment thereof that binds the first ATP7B signature peptide; and/or
a second ATP7B signature peptide of WD of SEQ ID NO: 11 or 21 with an antibody or antigen-binding fragment thereof that binds the second ATP7B signature peptide and comprises: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 57, CDR2 of SEQ ID NO: 58, and CDR3 of SEQ ID NO: 59, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 60, CDR2 of SEQ ID NO: 61, and CDR3 of SEQ ID NO: 62;
a third ATP7B signature peptide of WD of SEQ ID NO: 16 with an antibody or antigen-binding fragment thereof that binds the third ATP7B signature peptide;
a fourth ATP7B signature peptide of WD of SEQ ID NO: 17 with an antibody or antigen-binding fragment thereof that binds the fourth ATP7B signature peptide;
a fifth ATP7B signature peptide of WD of SEQ ID NO: 18 with an antibody or antigen-binding fragment thereof that binds the fifth ATP7B signature peptide;
a sixth ATP7B signature peptide of WD of SEQ ID NO: 19 with an antibody or antigen-binding fragment thereof that binds the sixth ATP7B signature peptide; and/or
a seventh ATP7B signature peptide of WD of SEQ ID NO: 20 with an antibody or antigen-binding fragment thereof that binds the seventh ATP7B signature peptide;
Performing liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS) on the enriched peptides, thus detecting one or more signature peptides of WD in one or more DBS samples.

### Claim 104 (depends on 103)

The method of claim 103, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second ATP7B signature peptide of WD of SEQ ID NO: 11 or 21 comprises a VH domain of SEQ ID NO: 75.

### Claim 105 (depends on 103)

The method of claim 103, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second ATP7B signature peptide of WD of SEQ ID NO: 11 or 21 comprises a VL domain of SEQ ID NO: 76.

### Claim 106 (depends on 103)

The method of claim 103, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second ATP7B signature peptide of WD of SEQ ID NO: 11 or 21 comprises a heavy chain of SEQ ID NO: 136.

### Claim 107 (depends on 103)

The method of claim 103, wherein the antibody or antigen-binding fragment thereof used for enrichment of the second ATP7B signature peptide of WD of SEQ ID NO: 11 or 21 comprises a light chain of SEQ ID NO: 141.

### Claim 108

An assay for the screening of severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), X-linked agammaglobulinemia (XLA) in a subject, and/or Wilson Disease (WD), the assay comprising:
(i) an antibody or antigen-binding fragment thereof comprising:
a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 22, CDR2 of SEQ ID NO: 23, and CDR3 of SEQ ID NO: 24, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 25, CDR2 of SEQ ID NO: 26, and CDR3 of SEQ ID NO: 27 that binds to a CD3ε signature peptide of SCID of SEQ ID NO: 1;
a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 28, CDR2 of SEQ ID NO: 29, and CDR3 of SEQ ID NO: 30, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 31, CDR2 of SEQ ID NO: 32, and CDR3 of SEQ ID NO: 33 that binds to a WASp signature peptide of WAS of SEQ ID NO: 2;
a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 34, CDR2 of SEQ ID NO: 35, and CDR3 of sequence GDI, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 36, CDR2 of SEQ ID NO: 37, and CDR3 of SEQ ID NO: 38 that binds to a BTK signature peptide of XLA of SEQ ID NO: 4; and/or
a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 57, CDR2 of SEQ ID NO: 58, and CDR3 of SEQ ID NO: 59, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 60, CDR2 of SEQ ID NO: 61, and CDR3 of SEQ ID NO: 62 that binds to an ATP7B peptide of SEQ ID NO: 11 or 21;
and/or
(ii) an antibody or antigen-binding fragment thereof that binds a WASp signature peptide of WAS of SEQ ID NO: 3;
an antibody or antigen-binding fragment thereof that binds a BTK signature peptide of XLA of SEQ ID NO: 5;
an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO: 10;
an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO: 16;
an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO: 17;
an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO: 18;
an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO: 19;
an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO: 20; and/or
an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO: 21;
and/or
(iii) reference signature peptides comprising:
a CD3ε peptide of SCID of SEQ ID NO: 1;
a WASp peptide of WAS of SEQ ID NO: 2;
a WASp peptide of WAS of SEQ ID NO: 3;
a BTK peptide of XLA of SEQ ID NO: 4;
a BTK peptide of XLA of SEQ ID NO: 5;
an ATP7B peptide of WD of SEQ ID NO: 10;
an ATP7B peptide of WD of SEQ ID NO: 11;
an ATP7B peptide of WD of SEQ ID NO: 16;
an ATP7B peptide of WD of SEQ ID NO: 17;
an ATP7B peptide of WD of SEQ ID NO: 18;
an ATP7B peptide of WD of SEQ ID NO: 19;
an ATP7B peptide of WD of SEQ ID NO: 20; and/or
an ATP7B peptide of WD of SEQ ID NO: 21.

### Claim 109 (depends on 108)

The assay of claim 108, wherein the antibody or antigen-binding fragment thereof that binds to the CD3ε signature peptide of SCID of SEQ ID NO: 1 comprises a VH domain of SEQ ID NO: 63.

### Claim 110 (depends on 108)

The assay of claim 108, wherein the antibody or antigen-binding fragment thereof that binds to the CD3ε signature peptide of SCID of SEQ ID NO: 1 comprises a VL domain of SEQ ID NO: 64.

### Claim 111 (depends on 108)

The assay of claim 108, wherein the antibody or antigen-binding fragment thereof that binds to the WASp signature peptide of WAS of SEQ ID NO: 2 comprises a VH domain of SEQ ID NO: 65.

### Claim 112 (depends on 108)

The assay of claim 108, wherein the antibody or antigen-binding fragment thereof that binds to the WASp signature peptide of WAS of SEQ ID NO: 2 comprises a VL domain of SEQ ID NO: 66.

### Claim 113 (depends on 108)

The assay of claim 108, wherein the antibody or antigen-binding fragment thereof that binds to the WASp signature peptide of WAS of SEQ ID NO: 2 comprises a heavy chain of SEQ ID NO: 86.

### Claim 114 (depends on 108)

The assay of claim 108, wherein the antibody or antigen-binding fragment thereof that binds to the WASp signature peptide of WAS of SEQ ID NO: 2 comprises a light chain of SEQ ID NO: 91.

### Claim 115 (depends on 108)

The assay of claim 108, wherein the antibody or antigen-binding fragment thereof that binds to the BTK signature peptide of XLA of SEQ ID NO: 4 comprises a VH domain of SEQ ID NO: 67.

### Claim 116 (depends on 108)

The assay of claim 108, wherein the antibody or antigen-binding fragment thereof that binds to the BTK signature peptide of XLA of SEQ ID NO: 4 comprises a VL domain of SEQ ID NO: 68.

### Claim 117 (depends on 108)

The assay of claim 108, wherein the antibody or antigen-binding fragment thereof that binds to the BTK signature peptide of XLA of SEQ ID NO: 4 comprises a heavy chain of SEQ ID NO: 96.

### Claim 118 (depends on 108)

The assay of claim 108, wherein the antibody or antigen-binding fragment thereof that binds to the BTK signature peptide of XLA of SEQ ID NO: 4 comprises a light chain of SEQ ID NO: 101.

### Claim 119 (depends on 108)

The assay of claim 108 to further screen for cystinosis, comprising:
(iii) an antibody or antigen-binding fragment thereof comprising:
a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 39, CDR2 of SEQ ID NO: 40, and CDR3 of SEQ ID NO: 41, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 42, CDR2 of SEQ ID NO: 43, and CDR3 of SEQ ID NO: 44 that binds to a CTNS signature peptide of cystinosis of SEQ ID NO: 6;
a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 45, CDR2 of SEQ ID NO: 46, and CDR3 of SEQ ID NO: 47, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 48, CDR2 of SEQ ID NO: 49, and CDR3 of SEQ ID NO: 50 that binds to a CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8;
a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 51, CDR2 of SEQ ID NO: 52, and CDR3 of SEQ ID NO: 53, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 54, CDR2 of SEQ ID NO: 55, and CDR3 of SEQ ID NO: 56 that binds to a SHPK signature peptide of cystinosis of SEQ ID NO: 9;
and/or
(iv) an antibody or antigen-binding fragment thereof that binds a CTNS signature peptide of SEQ ID NO: 12;
an antibody or antigen-binding fragment thereof that binds a CTNS signature peptide of SEQ ID NO: 13;
an antibody or antigen-binding fragment thereof that binds a SHPK signature peptide of SEQ ID NO: 14; and/or
an antibody or antigen-binding fragment thereof that binds a SHPK signature peptide of SEQ ID NO: 15;
and/or
(v) reference signature peptides comprising:
a CTNS peptide of cystinosis of SEQ ID NO: 6;
a CTNS peptide of cystinosis of SEQ ID NO: 7 or 8;
a CTNS peptide of cystinosis of SEQ ID NO: 12;
a CTNS peptide of cystinosis of SEQ ID NO: 13;
a SHPK peptide of cystinosis of SEQ ID NO: 9;
a SHPK peptide of cystinosis of SEQ ID NO: 14; and/or
a SHPK peptide of cystinosis of SEQ ID NO: 15.

### Claim 120 (depends on 119)

The assay of claim 119, wherein the antibody or antigen-binding fragment thereof that binds to the CTNS signature peptide of cystinosis of SEQ ID NO: 6 comprises a VH domain of SEQ ID NO: 69.

### Claim 121 (depends on 119)

The assay of claim 119, wherein the antibody or antigen-binding fragment thereof that binds to the CTNS signature peptide of cystinosis of SEQ ID NO: 6 comprises a VL domain of SEQ ID NO: 70.

### Claim 122 (depends on 119)

The assay of claim 119, wherein the antibody or antigen-binding fragment thereof that binds to the CTNS signature peptide of cystinosis of SEQ ID NO: 6 comprises a heavy chain of SEQ ID NO: 106.

### Claim 123 (depends on 119)

The assay of claim 119, wherein the antibody or antigen-binding fragment thereof that binds to the CTNS signature peptide of cystinosis of SEQ ID NO: 6 comprises a light chain of SEQ ID NO: 111.

### Claim 124 (depends on 119)

The assay of claim 119, wherein the antibody or antigen-binding fragment thereof that binds to the CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 comprises a VH domain of SEQ ID NO: 71.

### Claim 125 (depends on 119)

The assay of claim 119, wherein the antibody or antigen-binding fragment thereof that binds to the CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 comprises a VL domain of SEQ ID NO: 72.

### Claim 126 (depends on 119)

The assay of claim 119, wherein the antibody or antigen-binding fragment thereof that binds to the CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 comprises a heavy chain of SEQ ID NO: 116.

### Claim 127 (depends on 119)

The assay of claim 119, wherein the antibody or antigen-binding fragment thereof that binds to the CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8 comprises a light chain of SEQ ID NO: 121.

### Claim 128 (depends on 119)

The assay of claim 119, wherein the antibody or antigen-binding fragment thereof that binds to the SHPK signature peptide of cystinosis of SEQ ID NO: 9 comprises a VH domain of SEQ ID NO: 73.

### Claim 129 (depends on 119)

The assay of claim 119, wherein the antibody or antigen-binding fragment thereof that binds to the SHPK signature peptide of cystinosis of SEQ ID NO: 9 comprises a VL domain of SEQ ID NO: 74.

### Claim 130 (depends on 119)

The assay of claim 119, wherein the antibody or antigen-binding fragment thereof that binds to the SHPK signature peptide of cystinosis of SEQ ID NO: 9 comprises a heavy chain of SEQ ID NO: 126.

### Claim 131 (depends on 119)

The assay of claim 119, wherein the antibody or antigen-binding fragment thereof that binds to the SHPK signature peptide of cystinosis of SEQ ID NO: 9 comprises a light chain of SEQ ID NO: 131.

### Claim 132 (depends on 119)

The assay of claim 119, wherein the antibody or antigen-binding fragment thereof that binds to the ATP7B signature peptide of WD of SEQ ID NO: 11 or 21 comprises a VH domain of SEQ ID NO: 75.

### Claim 133 (depends on 119)

The assay of claim 119, wherein the antibody or antigen-binding fragment thereof that binds to the ATP7B signature peptide of WD of SEQ ID NO: 11 or 21 comprises a VL domain of SEQ ID NO: 76.

### Claim 134 (depends on 119)

The assay of claim 119, wherein the antibody or antigen-binding fragment thereof that binds to the ATP7B signature peptide of WD of SEQ ID NO: 11 or 21 comprises a heavy chain of SEQ ID NO: 136.

### Claim 135 (depends on 119)

The assay of claim 119, wherein the antibody or antigen-binding fragment thereof that binds to the ATP7B signature peptide of WD of SEQ ID NO: 11 or 21 comprises a light chain of SEQ ID NO: 141.

### Claim 136 (depends on 119)

The assay of claim 119, wherein the reference signature peptides are isotopically labeled.

### Claim 137 (depends on 119)

The assay of claim 119, wherein the antibodies or antigen-binding fragments thereof are attached to magnetic beads.

### Claim 138

An isolated antibody or antigen binding fragment thereof comprising: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 22, CDR2 of SEQ ID NO: 23, and CDR3 of SEQ ID NO: 24, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 25, CDR2 of SEQ ID NO: 26, and CDR3 of SEQ ID NO: 27.

### Claim 139 (depends on 138)

The isolated antibody or antigen binding fragment thereof of claim 138, wherein the VH domain comprises SEQ ID NO: 63.

### Claim 140 (depends on 138)

The isolated antibody or antigen binding fragment thereof of claim 138, wherein the VL domain comprises SEQ ID NO: 64.

### Claim 141

An isolated antibody or antigen binding fragment thereof comprising: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 28, CDR2 of SEQ ID NO: 29, and CDR3 of SEQ ID NO: 30, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 31, CDR2 of SEQ ID NO: 32, and CDR3 of SEQ ID NO: 33.

### Claim 142 (depends on 141)

The isolated antibody or antigen binding fragment thereof of claim 141, wherein the VH domain comprises SEQ ID NO: 65.

### Claim 143 (depends on 141)

The isolated antibody or antigen binding fragment thereof of claim 141, wherein the VL domain comprises SEQ ID NO: 66.

### Claim 144 (depends on 141)

The isolated antibody or antigen binding fragment thereof of claim 141, wherein the heavy chain comprises SEQ ID NO: 86.

### Claim 145 (depends on 141)

The isolated antibody or antigen binding fragment thereof of claim 141, wherein the light chain comprises SEQ ID NO: 91.

### Claim 146

An isolated antibody or antigen binding fragment thereof comprising: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 34, CDR2 of SEQ ID NO: 35, and CDR3 of sequence GDI, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 36, CDR2 of SEQ ID NO: 37, and CDR3 of SEQ ID NO: 38.

### Claim 147 (depends on 146)

The isolated antibody or antigen binding fragment thereof of claim 146, wherein the VH domain comprises SEQ ID NO: 67.

### Claim 148 (depends on 146)

The isolated antibody or antigen binding fragment thereof of claim 146, wherein the VL domain comprises SEQ ID NO: 68.

### Claim 149 (depends on 146)

The isolated antibody or antigen binding fragment thereof of claim 146, wherein the heavy chain comprises SEQ ID NO: 96.

### Claim 150 (depends on 146)

The isolated antibody or antigen binding fragment thereof of claim 146, wherein the light chain comprises SEQ ID NO: 101.

### Claim 151

An isolated antibody or antigen binding fragment thereof comprising: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 39, CDR2 of SEQ ID NO: 40, and CDR3 of SEQ ID NO: 41, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 42, CDR2 of SEQ ID NO: 43, and CDR3 of SEQ ID NO: 44.

### Claim 152 (depends on 151)

The isolated antibody or antigen binding fragment thereof of claim 151, wherein the VH domain comprises SEQ ID NO: 69.

### Claim 153 (depends on 151)

The isolated antibody or antigen binding fragment thereof of claim 151, wherein the VL domain comprises SEQ ID NO: 70.

### Claim 154 (depends on 151)

The isolated antibody or antigen binding fragment thereof of claim 151, wherein the heavy chain comprises SEQ ID NO: 106.

### Claim 155 (depends on 151)

The isolated antibody or antigen binding fragment thereof of claim 151, wherein the light chain comprises SEQ ID NO: 111.

### Claim 156

An isolated antibody or antigen binding fragment thereof comprising: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 45, CDR2 of SEQ ID NO: 46, and CDR3 of SEQ ID NO: 47, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 48, CDR2 of SEQ ID NO: 49, and CDR3 of SEQ ID NO: 50.

### Claim 157 (depends on 156)

The isolated antibody or antigen binding fragment thereof of claim 156, wherein the VH domain comprises SEQ ID NO: 71.

### Claim 158 (depends on 156)

The isolated antibody or antigen binding fragment thereof of claim 156, wherein the VL domain comprises SEQ ID NO: 72.

### Claim 159 (depends on 156)

The isolated antibody or antigen binding fragment thereof of claim 156, wherein the heavy chain comprises SEQ ID NO: 116.

### Claim 160 (depends on 156)

The isolated antibody or antigen binding fragment thereof of claim 156, wherein the light chain comprises SEQ ID NO: 121.

### Claim 161

An isolated antibody or antigen binding fragment thereof comprising: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 51, CDR2 of SEQ ID NO: 52, and CDR3 of SEQ ID NO: 53, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 54, CDR2 of SEQ ID NO: 55, and CDR3 of SEQ ID NO: 56.

### Claim 162 (depends on 161)

The isolated antibody or antigen binding fragment thereof of claim 161, wherein the VH domain comprises SEQ ID NO: 73.

### Claim 163 (depends on 161)

The isolated antibody or antigen binding fragment thereof of claim 161, wherein the VL domain comprises SEQ ID NO: 74.

### Claim 164 (depends on 161)

The isolated antibody or antigen binding fragment thereof of claim 161, wherein the heavy chain comprises SEQ ID NO: 126.

### Claim 165 (depends on 161)

The isolated antibody or antigen binding fragment thereof of claim 161, wherein the light chain comprises SEQ ID NO: 131.

### Claim 166

An isolated antibody or antigen binding fragment thereof comprising: a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 57, CDR2 of SEQ ID NO: 58, and CDR3 of SEQ ID NO: 59, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 60, CDR2 of SEQ ID NO: 61, and CDR3 of SEQ ID NO: 62.

### Claim 167 (depends on 166)

The isolated antibody or antigen binding fragment thereof of claim 166, wherein the VH domain comprises SEQ ID NO: 75.

### Claim 168 (depends on 166)

The isolated antibody or antigen binding fragment thereof of claim 166, wherein the VL domain comprises SEQ ID NO: 76.

### Claim 169 (depends on 166)

The isolated antibody or antigen binding fragment thereof of claim 166, wherein the heavy chain comprises SEQ ID NO: 136.

### Claim 170 (depends on 166)

The isolated antibody or antigen binding fragment thereof of claim 166, wherein the light chain comprises SEQ ID NO: 141.

### Claim 171

A kit comprising:
(i) an antibody or antigen-binding fragment thereof comprising:
a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 22, CDR2 of SEQ ID NO: 23, and CDR3 of SEQ ID NO: 24, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 25, CDR2 of SEQ ID NO: 26, and CDR3 of SEQ ID NO: 27 that binds to a CD3ε signature peptide of SCID of SEQ ID NO: 1;
a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 28, CDR2 of SEQ ID NO: 29, and CDR3 of SEQ ID NO: 30, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 31, CDR2 of SEQ ID NO: 32, and CDR3 of SEQ ID NO: 33 that binds to a WASp signature peptide of WAS of SEQ ID NO: 2;
a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 34, CDR2 of SEQ ID NO: 35, and CDR3 of sequence GDI, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 36, CDR2 of SEQ ID NO: 37, and CDR3 of SEQ ID NO: 38 that binds to a BTK signature peptide of XLA of SEQ ID NO: 4;
a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 39, CDR2 of SEQ ID NO: 40, and CDR3 of SEQ ID NO: 41, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 42, CDR2 of SEQ ID NO: 43, and CDR3 of SEQ ID NO: 44 that binds to a CTNS signature peptide of cystinosis of SEQ ID NO: 6;
a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 45, CDR2 of SEQ ID NO: 46, and CDR3 of SEQ ID NO: 47, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 48, CDR2 of SEQ ID NO: 49, and CDR3 of SEQ ID NO: 50 that binds to a CTNS signature peptide of cystinosis of SEQ ID NO: 7 or 8;
a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 51, CDR2 of SEQ ID NO: 52, and CDR3 of SEQ ID NO: 53, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 54, CDR2 of SEQ ID NO: 55, and CDR3 of SEQ ID NO: 56 that binds to a SHPK signature peptide of cystinosis of SEQ ID NO: 9; and/or
a heavy chain variable (VH) domain comprising CDR1 of SEQ ID NO: 57, CDR2 of SEQ ID NO: 58, and CDR3 of SEQ ID NO: 59, and a light chain variable (VL) domain comprising: CDR1 of SEQ ID NO: 60, CDR2 of SEQ ID NO: 61, and CDR3 of SEQ ID NO: 62 that binds to an ATP7B peptide of SEQ ID NO: 11 or 21;
and/or
(ii) an antibody or antigen-binding fragment thereof that binds a WASp signature peptide of WAS of SEQ ID NO: 3;
an antibody or antigen-binding fragment thereof that binds a BTK signature peptide of XLA of SEQ ID NO: 5;
an antibody or antigen-binding fragment thereof that binds a CTNS signature peptide of SEQ ID NO: 12;
an antibody or antigen-binding fragment thereof that binds a CTNS signature peptide of SEQ ID NO: 13;
an antibody or antigen-binding fragment thereof that binds a SHPK signature peptide of SEQ ID NO: 14;
an antibody or antigen-binding fragment thereof that binds a SHPK signature peptide of SEQ ID NO: 15;
an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO: 10;
an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO: 16;
an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO: 17;
an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO: 18;
an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO: 19;
an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO: 20; and/or
an antibody or antigen-binding fragment thereof that binds an ATP7B signature peptide of SEQ ID NO: 21;
and/or
(iii) reference signature peptides comprising:
a CD3ε peptide of SCID of SEQ ID NO: 1;
a WASp peptide of WAS of SEQ ID NO: 2;
a WASp peptide of WAS of SEQ ID NO: 3;
a BTK peptide of XLA of SEQ ID NO: 4;
a BTK peptide of XLA of SEQ ID NO: 5;
a CTNS peptide of cystinosis of SEQ ID NO: 6;
a CTNS peptide of cystinosis of SEQ ID NO: 7 or 8;
a CTNS peptide of cystinosis of SEQ ID NO: 12;
a CTNS peptide of cystinosis of SEQ ID NO: 13;
a SHPK peptide of cystinosis of SEQ ID NO: 9;
a SHPK peptide of cystinosis of SEQ ID NO: 14;
a SHPK peptide of cystinosis of SEQ ID NO: 15;
an ATP7B peptide of WD of SEQ ID NO: 10;
an ATP7B peptide of WD of SEQ ID NO: 11;
an ATP7B peptide of WD of SEQ ID NO: 16;
an ATP7B peptide of WD of SEQ ID NO: 17;
an ATP7B peptide of WD of SEQ ID NO: 18;
an ATP7B peptide of WD of SEQ ID NO: 19;
an ATP7B peptide of WD of SEQ ID NO: 20; and/or
an ATP7B peptide of WD of SEQ ID NO: 21.

### Claim 172 (depends on 171)

The kit of claim 171, further comprising one or more of filter paper card, punch tool, digestion enzymes, digestion buffers, solid support for the antibodies or antigen-binding fragments thereof; and elution buffers.

### Claim 173 (depends on 171)

The kit of claim 171, wherein the reference signature peptides are isotopically labeled.

### Claim 174 (depends on 171)

The kit of claim 171, wherein the antibodies or antigen-binding fragments thereof are attached to magnetic beads.

### Claim 175

A method of screening for severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), X-linked agammaglobulinemia (XLA), cystinosis, and/or Wilson disease (WD) in a subject, the method comprising:
Obtaining a dried blood spot (DBS) sample derived from the subject;
Digesting proteins from blood of the DBS with an enzyme to yield one or more peptides;
Enriching for:
a CD3ε signature peptide of SCID with an antibody or antigen-binding fragment thereof that binds to the CD3ε signature peptide;
a first WASp signature peptide of WAS with an antibody or antigen-binding fragment thereof that binds to the first WASp signature peptide;
a second WASp signature peptide of WAS with an antibody or antigen-binding fragment thereof that binds to the second WASp signature peptide;
a first BTK signature peptide of XLA with an antibody or antigen-binding fragment thereof that binds to the first BTK signature peptide;
a second BTK signature peptide with an antibody or antigen-binding fragment thereof that binds to the second BTK signature peptide;
a first CTNS signature peptide of cystinosis with an antibody or antigen-binding fragment thereof that binds to the first CTNS signature peptide;
a second CTNS signature peptide of cystinosis with an antibody or antigen-binding fragment thereof that binds to the second CTNS signature peptide;
a third CTNS signature peptide of cystinosis with an antibody or antigen-binding fragment thereof that binds to the third CTNS signature peptide;
a fourth CTNS signature peptide of cystinosis with an antibody or antigen-binding fragment thereof that binds to the fourth CTNS signature peptide;
a first SHPK signature peptide of cystinosis with an antibody or antigen-binding fragment thereof that binds to the first SHPK signature peptide;
a second SHPK signature peptide of cystinosis with an antibody or antigen-binding fragment thereof that binds to the second SHPK signature peptide; and/or
a third SHPK signature peptide of cystinosis with an antibody or antigen-binding fragment thereof that binds to the third SHPK signature peptide;
a first ATP7B signature peptide with an antibody or antigen-binding fragment thereof that binds to the first ATP7B signature peptide;
a second ATP7B signature peptide with an antibody or antigen-binding fragment thereof that binds to the second ATP7B signature peptide;
a third ATP7B signature peptide with an antibody or antigen-binding fragment that binds to the third ATP7B signature peptide;
a fourth ATP7B signature peptide with an antibody or antigen-binding fragment thereof that binds to the fourth ATP7B signature peptide;
a fifth ATP7B signature peptide with an antibody or antigen-binding fragment thereof that binds to the fifth ATP7B signature peptide;
a sixth ATP7B signature peptide with an antibody or antigen-binding fragment thereof that binds to the sixth ATP7B signature peptide; and/or
a seventh ATP7B signature peptide with an antibody or antigen-binding fragment thereof;
Performing liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS) on the enriched peptides to determine concentrations of the peptides; and
Diagnosing the subject with:
SCID when the concentration of the CD3ε signature peptide is lower than a predetermined threshold concentration or when the CD3ε signature peptide is absent;
WAS when the concentrations of the first and/or second WASp signature peptides are lower than corresponding predetermined threshold concentrations or when the first and/or second WASp signature peptides are absent;
XLA when the concentrations of the first and/or second BTK signature peptides are lower than corresponding predetermined threshold concentrations or when the first and/or second BTK signature peptides are absent;
cystinosis when the concentrations of the first CTNS, the second CTNS, the third CTNS, the fourth CTNS, the first SHPK, the second SHPK, and/or the third SHPK signature peptides are lower than corresponding predetermined threshold concentrations or when the first CTNS, the second CTNS, the third CTNS, the fourth CTNS, the first SHPK, the second SHPK, and/or the third SHPK signature peptides are absent; and/or
WD when the concentrations of the first ATP7B, the second ATP7B, the third ATP7B, the fourth ATP7B, the fifth ATP7B, the sixth ATP7B, and/or the seventh ATP7B signature peptides are lower than corresponding predetermined threshold concentrations or when the first ATP7B, the second ATP7B, the third ATP7B, the fourth ATP7B, the fifth ATP7B, the sixth ATP7B, and/or the seventh ATP7B signature peptides are absent.

### Claim 176 (depends on 175)

The method of claim 175, wherein
the CD3ε signature peptide of SCID is encoded by an amino acid sequence set forth in SEQ ID NO: 1;
the first WASp signature peptide of WAS is encoded by an amino acid sequence set forth in SEQ ID NO: 2;
the second WASp signature peptide of WAS is encoded by an amino acid sequence set forth in SEQ ID NO: 3;
the first BTK signature peptide of XLA is encoded by an amino acid sequence set forth in SEQ ID NO: 4; and/or
the second BTK signature peptide of XLA is encoded by an amino acid sequence set forth in SEQ ID NO: 5;
the first CTNS signature peptide of cystinosis is encoded by an amino acid sequence set forth in SEQ ID NO: 6;
the second CTNS signature peptide of cystinosis is encoded by an amino acid sequence set forth in SEQ ID NO: 7 or 8;
the third CTNS signature peptide of cystinosis is encoded by an amino acid sequence set forth in SEQ ID NO: 12;
the fourth CTNS signature peptide of cystinosis is encoded by an amino acid sequence set forth in SEQ ID NO: 13;
the first SHPK signature peptide of cystinosis is encoded by an amino acid sequence set forth in SEQ ID NO: 9;
the second SHPK signature peptide of cystinosis is encoded by an amino acid sequence set forth in SEQ ID NO: 14;
the third SHPK signature peptide of cystinosis is encoded by an amino acid sequence set forth in SEQ ID NO: 15;
the first ATP7B signature peptide of WD is encoded by an amino acid sequence set forth in SEQ ID NO: 10;
the second ATP7B signature peptide of WD is encoded by an amino acid sequence set forth in SEQ ID NO: 11 or 21;
the third ATP7B signature peptide of WD is encoded by an amino acid sequence set forth in SEQ ID NO: 16;
the fourth ATP7B signature peptide of WD is encoded by an amino acid sequence set forth in SEQ ID NO: 17;
the fifth ATP7B signature peptide of WD is encoded by an amino acid sequence set forth in SEQ ID NO: 18;
the sixth ATP7B signature peptide of WD is encoded by an amino acid sequence set forth in SEQ ID NO: 19; and/or
the seventh ATP7B signature peptide of WD is encoded by an amino acid sequence set forth in SEQ ID NO: 20.

### Claim 177 (depends on 175)

The method of claim 175, wherein
the antibody or antigen-binding fragment thereof that binds to the CD3ε signature peptide includes: a heavy chain variable (VH) domain including CDR1 of SEQ ID NO: 22, CDR2 of SEQ ID NO: 23, and CDR3 of SEQ ID NO: 24, and a light chain variable (VL) domain including: CDR1 of SEQ ID NO: 25, CDR2 of SEQ ID NO: 26, and CDR3 of SEQ ID NO: 27;
the antibody or antigen-binding fragment thereof that binds to the first WASp signature peptide includes: a heavy chain variable (VH) domain including CDR1 of SEQ ID NO: 28, CDR2 of SEQ ID NO: 29, and CDR3 of SEQ ID NO: 30, and a light chain variable (VL) domain including: CDR1 of SEQ ID NO: 31, CDR2 of SEQ ID NO: 32, and CDR3 of SEQ ID NO: 33; and/or
the antibody or antigen-binding fragment thereof that binds to the first BTK signature peptide includes: a heavy chain variable (VH) domain including CDR1 of SEQ ID NO: 34, CDR2 of SEQ ID NO: 35, and CDR3 of sequence GDI, and a light chain variable (VL) domain including: CDR1 of SEQ ID NO: 36, CDR2 of SEQ ID NO: 37, and CDR3 of SEQ ID NO: 38;
the antibody or antigen-binding fragment thereof that binds to the first CTNS signature peptide of cystinosis includes: a heavy chain variable (VH) domain including CDR1 of SEQ ID NO: 39, CDR2 of SEQ ID NO: 40, and CDR3 of SEQ ID NO: 41, and a light chain variable (VL) domain including: CDR1 of SEQ ID NO: 42, CDR2 of SEQ ID NO: 43, and CDR3 of SEQ ID NO: 44;
the antibody or antigen-binding fragment thereof that binds to the second CTNS signature peptide includes: a heavy chain variable (VH) domain including CDR1 of SEQ ID NO: 45, CDR2 of SEQ ID NO: 46, and CDR3 of SEQ ID NO: 47, and a light chain variable (VL) domain including: CDR1 of SEQ ID NO: 48, CDR2 of SEQ ID NO: 49, and CDR3 of SEQ ID NO: 50;
the antibody or antigen-binding fragment thereof that binds to the first SHPK signature peptide includes: a heavy chain variable (VH) domain including CDR1 of SEQ ID NO: 51, CDR2 of SEQ ID NO: 52, and CDR3 of SEQ ID NO: 53, and a light chain variable (VL) domain including: CDR1 of SEQ ID NO: 54, CDR2 of SEQ ID NO: 55, and CDR3 of SEQ ID NO: 56; and/or
the antibody or antigen-binding fragment thereof that binds to the second ATP7B signature peptide includes: a heavy chain variable (VH) domain including CDR1 of SEQ ID NO: 57, CDR2 of SEQ ID NO: 58, and CDR3 of SEQ ID NO: 59, and a light chain variable (VL) domain including: CDR1 of SEQ ID NO: 60, CDR2 of SEQ ID NO: 61, and CDR3 of SEQ ID NO: 62.
